These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 15151477)
21. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Alagona P Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805 [TBL] [Abstract][Full Text] [Related]
22. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed? Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061 [TBL] [Abstract][Full Text] [Related]
24. [Treatment of dyslipidemia in clinical practice]. Paragh G; Harangi M Orv Hetil; 2006 Mar; 147(9):389-94. PubMed ID: 16619956 [TBL] [Abstract][Full Text] [Related]
25. Intensive lipid lowering with atorvastatin in coronary disease. Modest GA N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003833 [No Abstract] [Full Text] [Related]
26. Reducing the risk of coronary heart disease via lipid reduction. Spratt KA J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S9-13. PubMed ID: 15467018 [TBL] [Abstract][Full Text] [Related]
27. What is the most effective strategy for managing diabetic dyslipidaemia? Reasner CA Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442 [TBL] [Abstract][Full Text] [Related]
28. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Stone NJ; Bilek S; Rosenbaum S Am J Cardiol; 2005 Aug; 96(4A):53E-59E. PubMed ID: 16098845 [TBL] [Abstract][Full Text] [Related]
29. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276 [TBL] [Abstract][Full Text] [Related]
30. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335 [TBL] [Abstract][Full Text] [Related]
32. Changing face of dyslipidemia therapy. Banerjee AK Indian Heart J; 2008; 60(3):192-4. PubMed ID: 19240305 [No Abstract] [Full Text] [Related]
33. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). HMG-CoA reductase inhibitors: a review of published clinical trials and pharmacoeconomic evaluations. Int J Technol Assess Health Care; 1998; 14(2):396-8. PubMed ID: 9678976 [No Abstract] [Full Text] [Related]
34. The treatment of dyslipidemia--what's left in the pipeline? Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209 [TBL] [Abstract][Full Text] [Related]
35. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein. Backes JM; Gibson CA Ann Pharmacother; 2005 Mar; 39(3):523-6. PubMed ID: 15671087 [TBL] [Abstract][Full Text] [Related]